Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.25792
   PubMed Web of Science ®Google Scholar
• Nicholson E, Holyoake T. The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma. 2009;9(Suppl 4):S376–381. doi:10.3816/CLM.2009.s.037
   PubMedGoogle Scholar
• Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Ulster Med J. 2007;76(1):8–17.
   PubMedGoogle Scholar
• García-Gutiérrez V, Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9. doi:10.3389/fonc.2019.00603
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186–193. doi:10.1016/S2352-3026(15)00048-4
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol off J Am Soc Clin Oncol. 2017;35(3):298–305. doi:10.1200/JCO.2016.68.2914
   PubMed Web of Science ®Google Scholar
• Oka S, Muroi K, Mori M, et al. Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes. Leuk Lymphoma. 2009;50(2):290–293. doi:10.1080/10428190802627598
   PubMed Web of Science ®Google Scholar
• Kang ZJ, Liu YF, Xu LZ, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2022;35:48. doi:10.1186/s40880-016-0108-0
   Google Scholar
• Holmberg M. Is the primary event in radiation-induced chronic myelogenous leukemia the induction of the t(9;22) translocation? Leuk Res. 1992;16(4):333–336. doi:10.1016/0145-2126(92)90134-S
   PubMed Web of Science ®Google Scholar
• Ismail SI, Naffa RG, Yousef AMF, Ghanim MT. Incidence of bcr‑abl fusion transcripts in healthy individuals. Mol Med Rep. 2014;9(4):1271–1276. doi:10.3892/mmr.2014.1951
   PubMed Web of Science ®Google Scholar
• Aplan PD. Causes of oncogenic chromosomal translocation. Trends Genet TIG. 2006;22(1):46–55. doi:10.1016/j.tig.2005.10.002
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood. 2022;113(8):1619–1630. doi:10.1182/blood-2008-03-144790
   Google Scholar
• Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009;114(11):2232–2235. doi:10.1182/blood-2009-02-204693
   PubMed Web of Science ®Google Scholar
• Arun AK, Senthamizhselvi A, Mani S, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol. 2017;39(3):235–242. doi:10.1111/ijlh.12616
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Beran M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer. 1995;75(2):464–470. doi:10.1002/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Seong D, Kantarjian HM, Albitar M, et al. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol off J Eur Soc Med Oncol. 1999;10(8):955–959. doi:10.1023/A:1008349405763
   PubMed Web of Science ®Google Scholar
• Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002;95(8):1673–1684. doi:10.1002/cncr.10832
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Ohyashiki K, Ito H, Toyama K. Molecular and clinical investigations in Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer Genet Cytogenet. 1988;33(1):119–126. doi:10.1016/0165-4608(88)90057-X
   PubMedGoogle Scholar
• Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–2651. doi:10.1182/blood-2014-02-553800
   PubMed Web of Science ®Google Scholar
• Diamantopoulos PT, Viniou NA. Atypical chronic myelogenous leukemia, BCR-ABL1 negative: diagnostic criteria and treatment approaches. Front Oncol. 2021;11:722507. doi:10.3389/fonc.2021.722507
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264. doi:10.1172/JCI41246
   PubMed Web of Science ®Google Scholar
• Yohannan B, George B. B-lymphoid blast phase–chronic myeloid leukemia: current therapeutics. Int J Mol Sci. 2022;23(19):11836. doi:10.3390/ijms231911836
   PubMed Web of Science ®Google Scholar
• Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12):3746–3753. doi:10.1182/blood-2004-05-1941
   PubMed Web of Science ®Google Scholar
• Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319–327. doi:10.1182/blood-2005-07-2815
   PubMed Web of Science ®Google Scholar
• Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer. 2002;2(5):351–360. doi:10.1038/nrc799
   PubMed Web of Science ®Google Scholar
• Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(Suppl 2):107–121. doi:10.1007/s00277-015-2325-z
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood.2009;113(8):1619–1630. doi:10.1182/blood-2008-03-144790
   PubMed Web of Science ®Google Scholar
• How HR. I treat CML blast crisis. Blood. 2012;120(4):737–747. doi:10.1182/blood-2012-03-380147
   PubMed Web of Science ®Google Scholar
• Adnan Awad S, Dufva O, Ianevski A, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087–1099. doi:10.1038/s41375-020-01011-5
   PubMed Web of Science ®Google Scholar
• Ochi Y, Yoshida K, Huang YJ, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12(1):2833. doi:10.1038/s41467-021-23097-w
   PubMed Web of Science ®Google Scholar
• Soliman DS, Amer AM, Mudawi D, et al. Chronic myeloid leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation. Acta Bio. 2018;89(3–S):38–44.
   Google Scholar
• Zagaria A, Anelli L, Albano F, et al. A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet. 2004;150(1):81–85. doi:10.1016/j.cancergencyto.2003.08.018
   PubMedGoogle Scholar
• Alhuraiji A, Kantarjian H, Boddu P, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93(1):84–90. doi:10.1002/ajh.24943
   PubMed Web of Science ®Google Scholar
• Krishna Chandran R, Geetha N, Sakthivel KM, Suresh Kumar R, Jagathnath Krishna KMN, Sreedharan H. Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia. Front Oncol. 2019;5(9):88. doi:10.3389/fonc.2019.00088
   Google Scholar
• Chen Z, Shao C, Wang W, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31(3):585–592. doi:10.1038/leu.2016.231
   PubMed Web of Science ®Google Scholar
• Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102–1109. doi:10.1182/bloodadvances.2020003570
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol. 2012;127(1):34–42.
   PubMed Web of Science ®Google Scholar
• Siti Mariam I, Norhidayah R, Zulaikha AB, et al. Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. Front Oncol. 2022;12. doi:10.3389/fonc.2022.720845
   PubMed Web of Science ®Google Scholar
• Houshmand M, Simonetti G, Circosta P, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33(7):1543–1556. doi:10.1038/s41375-019-0490-0
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926–935. doi:10.1038/sj.leu.2404609
   PubMed Web of Science ®Google Scholar
• Kavalerchik E, Goff D, Jamieson CHM. Chronic myeloid leukemia stem cells. J Clin Oncol off J Am Soc Clin Oncol. 2008;26(17):2911–2915. doi:10.1200/JCO.2008.17.5745
   PubMed Web of Science ®Google Scholar
• Herrmann H, Cerny-Reiterer S, Gleixner KV, et al. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica. 2012;97(2):219–226. doi:10.3324/haematol.2010.035006
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov. 2014;13(7):497–512. doi:10.1038/nrd4253
   PubMed Web of Science ®Google Scholar
• Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol. 1993;11:245–268. doi:10.1146/annurev.iy.11.040193.001333
   PubMed Web of Science ®Google Scholar
• Sadovnik I, Herrmann H, Eisenwort G, et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp Hematol. 2022;51:17–24. doi:10.1016/j.exphem.2017.04.003
   Google Scholar
• Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123(25):3951–3962. doi:10.1182/blood-2013-10-536078
   PubMed Web of Science ®Google Scholar
• Gschwandtner M, Paulitschke V, Mildner M, et al. Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells. Allergy. 2017;72(1):85–97. doi:10.1111/all.12919
   PubMed Web of Science ®Google Scholar
• Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A. 2007;104(47):18660–18665. doi:10.1073/pnas.0705939104
   PubMed Web of Science ®Google Scholar
• Kinstrie R, Horne GA, Morrison H, et al. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia. 2020;34(6):1613–1625. doi:10.1038/s41375-019-0684-5
   PubMed Web of Science ®Google Scholar
• Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2022;118(20):5565–5572. doi:10.1182/blood-2010-12-327437
   Google Scholar
• Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458(7239):776–779. doi:10.1038/nature07737
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41(7):783–792. doi:10.1038/ng.389
   PubMed Web of Science ®Google Scholar
• Kuepper MK, Bütow M, Herrmann O, et al. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 2019;33(8):1964–1977. doi:10.1038/s41375-019-0427-7
   PubMed Web of Science ®Google Scholar
• Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595–1606. doi:10.1182/blood-2016-09-696013
   PubMed Web of Science ®Google Scholar
• Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma. 2008;49(4):610–614. doi:10.1080/03093640701859089
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 2008;68(8):2576–2580. doi:10.1158/0008-5472.CAN-07-6858
   PubMed Web of Science ®Google Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008;68(17):6884–6888. doi:10.1158/0008-5472.CAN-08-1101
   PubMed Web of Science ®Google Scholar
• Zhang B, Chu S, Agarwal P, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood. 2016;128(23):2671–2682. doi:10.1182/blood-2015-11-679928
   PubMed Web of Science ®Google Scholar
• Bhatia R. TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA. Trans Am Clin Climatol Assoc. 2019;130:246–254.
   PubMedGoogle Scholar
• Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol OncolJ Hematol Oncol. 2020;13(1):104. doi:10.1186/s13045-020-00937-8
   PubMed Web of Science ®Google Scholar
• Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014;124(9):1492–1501. doi:10.1182/blood-2013-12-545640
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017;1(28):iv41–51. doi:10.1093/annonc/mdx219
   Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2020;18(10):1385–1415. doi:10.6004/jnccn.2020.0047
   PubMed Web of Science ®Google Scholar
• Asnafi AA, Deris Zayeri Z, Shahrabi S, Zibara K, Vosughi T. Chronic myeloid leukemia with complex karyotypes: prognosis and therapeutic approaches. J Cell Physiol. 2019;234(5):5798–5806. doi:10.1002/jcp.27505
   PubMed Web of Science ®Google Scholar
• ClinicalKey. Chronic myeloid leukemia; 2022. Available from: https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323357623000676?scrollTo=%23hl0000264. Accessed February 10, 2023.
   Google Scholar
• Arunachalam AK, Jain M, Kumar A, Kushwaha R, Singh US, Tripathi AK. Megakaryocytes in chronic phase of chronic myeloid leukemia: a descriptive case series. Ann Pathol Lab Med. 2016;3(3):A176–182.
   Google Scholar
• Mughal Z, Babar H, Ashraf S, Hamid A, Khokhar A, Qamar S. Megakaryocytic clustering in chronic myeloid leukemia: can it be a predictor of clinical outcome? J Coll Physicians Surg. 2021;31(1):34–38. doi:10.29271/jcpsp.2021.01.34
   PubMed Web of Science ®Google Scholar
• Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59(10):1739–1743. doi:10.1002/1097-0142(19870515)59:10<1739::AID-CNCR2820591011>3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Haznedaroğlu İC, Kuzu I, Ilhan O. WHO 2016 definition of chronic myeloid leukemia and tyrosine kinase inhibitors. Turk J Hematol. 2020;37(1):42–47.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Ivanov S, Sharma P, Jobanputra Y, Zhang Y. Transformation of chronic myeloid leukemia to acute biphenotypic leukemia. J Med Cases. 2020;11(8):239–242. doi:10.14740/jmc3511
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Padhi P, Topalovski M, El Behery R, Cantu ES, Medavarapu R, Rare A. Case of chronic myelogenous leukemia presenting as T-cell lymphoblastic crisis. Case Rep Oncol Med. 2018;2018:7276128. doi:10.1155/2018/7276128
   PubMedGoogle Scholar
• Andretta E, Costa C, Longobardi C, et al. Potential approaches versus approved or developing chronic myeloid leukemia therapy. Front Oncol. 2022;11:801779. doi:10.3389/fonc.2021.801779
   Web of Science ®Google Scholar
• Simonsson B, Gedde-Dahl T, Markevärn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118(12):3228–3235. doi:10.1182/blood-2011-02-336685
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–2521. doi:10.1056/NEJMoa1004095
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Pfirrmann M, Zander A, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016;30(3):562–569. doi:10.1038/leu.2015.281
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. doi:10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2022;2014:357027.
   Google Scholar
• Uzer E, Ünal A, Köker MY, Doğan SA. The Side Effects of Imatinib. Turk J Hematol. 2022;30(3):341. doi:10.4274/TJH-2011.0018
   Google Scholar
• Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol Targets Ther. 2010;2(4):315–323. doi:10.2147/BTT.S5775
   Google Scholar
• Prost S, Le Dantec M, Augé S, et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/STAT5 signaling pathway in macaques. J Clin Invest. 2008;118(5):1765–1775. doi:10.1172/JCI33037
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Second-Generation Tyrosine Kinase Inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs. Mediterr J Hematol Infect Dis. 2014;6(1):e2014003. doi:10.4084/mjhid.2014.003
   PubMedGoogle Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol off J Am Soc Clin Oncol. 2016;34(20):2333–2340. doi:10.1200/JCO.2015.64.8899
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jiang Q, Wang J, et al. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020;34(8):2064–2073. doi:10.1038/s41375-020-0805-1
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054. doi:10.1038/leu.2016.5
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(3):231–237. doi:10.1200/JCO.2017.74.7162
   PubMed Web of Science ®Google Scholar
• Do YR, Kwak JY, Kim JA, et al. Long-term data from a Phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol. 2020;189(2):303–312. doi:10.1111/bjh.16381
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. doi:10.1016/j.ccr.2009.09.028
   PubMed Web of Science ®Google Scholar
• Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011;77(1):1–11. doi:10.1111/j.1747-0285.2010.01054.x
   PubMed Web of Science ®Google Scholar
• Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020;4(3):530–538. doi:10.1182/bloodadvances.2019000268
   PubMed Web of Science ®Google Scholar
• Alves R, Gonçalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820. doi:10.3390/cancers13194820
   PubMed Web of Science ®Google Scholar
• Meenakshi Sundaram DN, Jiang X, Brandwein JM, Valencia-Serna J, Remant KC, Uludağ H. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today. 2019;24(7):1355–1369. doi:10.1016/j.drudis.2019.05.007
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796. doi:10.1056/NEJMoa1306494
   PubMed Web of Science ®Google Scholar
• Galinsky I, Buchanan S. Guide to interpreting disease responses in chronic myeloid leukemia. J Adv Pract Oncol. 2022;3(4):225–236.
   Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–1820. doi:10.1182/blood-2006-02-005686
   PubMed Web of Science ®Google Scholar
• Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica. 2022;105(12):2730–2737. doi:10.3324/haematol.2019.240739
   Web of Science ®Google Scholar
• Ebian HF, Abdelnabi ASM, Abdelazem AS, Khamis T, Fawzy HM, Hussein S. Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia. Leuk Res Rep. 2022;17:100321. doi:10.1016/j.lrr.2022.100321
   PubMedGoogle Scholar
• Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, et al. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India. Ecancermedicalscience. 2022;10:679.
   Google Scholar
• Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2022;34(8).
   Web of Science ®Google Scholar
• Munje C, Copland M. Exploring stem cell heterogeneity in chronic myeloid leukemia. Trends Cancer. 2022;4(3):167–169. doi:10.1016/j.trecan.2017.12.001
   Google Scholar
• Jeanpierre S, Arizkane K, Thongjuea S, et al. The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. Haematologica. 2022;106(1):111–122. doi:10.3324/haematol.2019.232793
   Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035. doi:10.1016/S1470-2045(10)70233-3
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717–723. doi:10.3324/haematol.2015.139899
   PubMed Web of Science ®Google Scholar
• Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer Oxf Engl. 2017;77:48–56.
   PubMed Web of Science ®Google Scholar
• Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191(3):433–441. doi:10.1111/bjh.16718
   PubMed Web of Science ®Google Scholar
• Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108–1116. doi:10.1038/leu.2016.360
   PubMed Web of Science ®Google Scholar
• Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35(5):1344–1355. doi:10.1038/s41375-021-01205-5
   PubMed Web of Science ®Google Scholar
• Diral E, Mori S, Antolini L, et al. Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood. 2020;136(19):2237–2240. doi:10.1182/blood.2019004371
   PubMed Web of Science ®Google Scholar
• Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218–25. doi:10.1016/S2352-3026(19)30235-2
   PubMed Web of Science ®Google Scholar
• Fava C, Rege-Cambrin G, Dogliotti I, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104(8):1589–1596. doi:10.3324/haematol.2018.205054
   PubMed Web of Science ®Google Scholar
• Pagnano KB, Seguro FS, Miranda EC, et al. Duration of major molecular response and discontinuation in deep molecular response (MR4.5) were associated with longer treatment-free survival after imatinib discontinuation - results from two prospective Brazilian trials. Blood. 2019;134:1655. doi:10.1182/blood-2019-125368
   Web of Science ®Google Scholar
• Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650–659. doi:10.1080/10428194.2019.1675879
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Matsumura I, Shimose T, et al. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). Int J Hematol. 2019;110(6):675–682. doi:10.1007/s12185-019-02736-5
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757. doi:10.1016/S1470-2045(18)30192-X
   PubMed Web of Science ®Google Scholar
• Takahashi N, Tauchi T, Kitamura K, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185–193. doi:10.1007/s12185-017-2334-x
   PubMed Web of Science ®Google Scholar
• Kumagai T, Nakaseko C, Nishiwaki K, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182–192. doi:10.1111/cas.13430
   PubMed Web of Science ®Google Scholar
• Takahashi N, Nishiwaki K, Nakaseko C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835–1842. doi:10.3324/haematol.2018.194894
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Ueda Y, Usuki K, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019;24(4):445–453. doi:10.1007/s10147-018-1368-2
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda JC, Pereira A, Pastor-Galán I, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018;8(10):91. doi:10.1038/s41408-018-0125-0
   PubMedGoogle Scholar
• Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461–470. doi:10.7326/M17-1094
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–1531. doi:10.1038/leu.2017.63
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–854. doi:10.1182/blood-2016-09-742205
   PubMed Web of Science ®Google Scholar
• Kim DDH, Bence-Bruckler I, Forrest DL, et al. Treatment-Free Remission Accomplished By Dasatinib (TRAD): preliminary results of the pan-Canadian tyrosine kinase inhibitor discontinuation trial. Blood. 2016;128(22):1922. doi:10.1182/blood.V128.22.1922.1922
   Web of Science ®Google Scholar
• Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–535. doi:10.1016/S2352-3026(15)00196-9
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522. doi:10.1182/blood-2013-02-483750
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(5):424–430. doi:10.1200/JCO.2012.48.5797
   PubMed Web of Science ®Google Scholar
• Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian cooperative trial for haemato-oncology (HOVON). Eur J Cancer Oxf Engl. 2013;49(15):3242–3246.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Nicolini FE, Noël MP, et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood. 2013;122(21):654. doi:10.1182/blood.V122.21.654.654
   Google Scholar
• Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res. 2012;36(6):689–693. doi:10.1016/j.leukres.2012.02.011
   PubMed Web of Science ®Google Scholar
• Matsuki E, Ono Y, Tonegawa K, et al. Detailed Investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib – an updated result of the keio STIM study. Blood. 2012;120(21):2788. doi:10.1182/blood.V120.21.2788.2788
   Web of Science ®Google Scholar
• Vigón L, Luna A, Galán M, et al. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission. J Clin Med. 2021;10(1):42. doi:10.3390/jcm10010042
   Web of Science ®Google Scholar
• Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102(8):1368–1377. doi:10.3324/haematol.2017.165001
   PubMed Web of Science ®Google Scholar
• Raspadori D, Pacelli P, Sicuranza A, et al. Flow cytometry assessment of CD26+ leukemic stem cells in peripheral blood: a simple and rapid new diagnostic tool for chronic myeloid leukemia. Cytometry B Clin Cytom. 2019;96(4):294–299. doi:10.1002/cyto.b.21764
   PubMed Web of Science ®Google Scholar
• Bocchia M, Sicuranza A, Abruzzese E, et al. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI Therapy and during treatment-free remission. Front Oncol. 2018;8:194. doi:10.3389/fonc.2018.00194
   PubMed Web of Science ®Google Scholar
• Stuckey R, López Rodríguez JF, Gómez-Casares MT. Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission. Curr Oncol Rep. 2022;24(4):415–426. doi:10.1007/s11912-022-01228-w
   PubMed Web of Science ®Google Scholar
• Cayssials E, Jacomet F, Piccirilli N, et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol. 2019;186(1):54–59. doi:10.1111/bjh.15858
   PubMed Web of Science ®Google Scholar
• Claudiani S, Apperley JF, Khan A, Khorashad J, Milojkovic D. Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations. Haematologica. 2020;105(5):e225–7. doi:10.3324/haematol.2019.234179
   PubMed Web of Science ®Google Scholar
• D’Adda M, Farina M, Schieppati F, et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer. 2019;125(10):1674–1682. doi:10.1002/cncr.31977
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Binotto G, Capodanno I, et al. Making Treatment-Free Remission (TFR) easier in chronic myeloid leukemia: fact-checking and practical management tools. Target Oncol. 2021;16(6):823–838. doi:10.1007/s11523-021-00831-4
   PubMed Web of Science ®Google Scholar
• Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910–914. doi:10.1002/ajh.24120
   PubMed Web of Science ®Google Scholar
• Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42–50. doi:10.1001/jamaoncol.2020.5774
   PubMed Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375–83. doi:10.1016/S2352-3026(19)30094-8
   PubMed Web of Science ®Google Scholar
• Atallah E, Treatment-Free Remission: SK. the New Goal in CML Therapy. Curr Hematol Malig Rep. 2021;16(5):433–439. doi:10.1007/s11899-021-00653-1
   PubMed Web of Science ®Google Scholar
• Kim DDH, Novitzky-Basso I, Kim TS, et al. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. Br J Haematol. 2021;193(4):779–791. doi:10.1111/bjh.17447
   PubMed Web of Science ®Google Scholar
• ECOG-ACRIN Cancer Research Group. Phase II study of adding the anti-PD-1 pembrolizumab to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03516279. Accessed February 10, 2023.
   Google Scholar
• Katagiri S, Tauchi T, Ando K, Okabe S, Gotoh M, Ohyashiki K. Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia. Leuk Res Rep. 2017;7:33–35. doi:10.1016/j.lrr.2017.04.002
   PubMedGoogle Scholar
• Richter J, Söderlund S, Lübking A, et al. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: a Tyrosine Kinase Inhibitor Withdrawal Syndrome? J Clin Oncol. 2014;32(25):2821–2823. doi:10.1200/JCO.2014.55.6910
   PubMed Web of Science ®Google Scholar
• Flynn KE, Atallah E, Lin L, et al. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022;107(11):2641–2649. doi:10.3324/haematol.2021.280377
   PubMed Web of Science ®Google Scholar